Article
Amyloid β oligomers enhance presynaptic exocytosis via CaV2.1 to drive disease progression in Alzheimer’s models
2024-09-30
Abstract excerpt
<title>Abstract</title> <p> Mixed outcomes in clinical trials of amyloid β-lowering agents for Alzheimer’s disease (AD) make the identification of alternative candidate molecular targets for therapy a priority. However, limited understanding of molecular pathways mediating the effects of amyloid β on synaptic and cognitive function hampers these efforts. Here, we uncover an ENaC-Ca <sub>V</sub> 2.3-PKC-GSK-3β...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f40aea72-1fb2-5b25-90f9-16c01df645a4
- DOI
- 10.21203/rs.3.rs-1638917/v1
